These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

940 related items for PubMed ID: 26058549

  • 41.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 42.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 43. Biosimilars in IBD: from theory to practice.
    Danese S, Bonovas S, Peyrin-Biroulet L.
    Nat Rev Gastroenterol Hepatol; 2017 Jan; 14(1):22-31. PubMed ID: 27729659
    [Abstract] [Full Text] [Related]

  • 44.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 45.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 46.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 47.
    ; 2017 01 18. PubMed ID: 28727394
    [Abstract] [Full Text] [Related]

  • 48. Biosimilars in inflammatory bowel diseases: an important moment for Brazilian gastroenterologists.
    Teixeira FV, Kotze PG, Damião AO, Miszputen SJ.
    Arq Gastroenterol; 2015 01 18; 52(1):76-80. PubMed ID: 26017088
    [Abstract] [Full Text] [Related]

  • 49.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 50.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 51.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 52. Biosimilars of Adalimumab in Inflammatory Bowel Disease: Are we Ready for that?
    Argollo M, Fiorino G, Gilardi D, Furfaro F, Roda G, Loy L, Allocca M, Peyrin-Biroulet L, Danese S.
    Curr Pharm Des; 2019 01 18; 25(1):7-12. PubMed ID: 30864505
    [Abstract] [Full Text] [Related]

  • 53. Safety, efficacy and immunogenicity of switching from innovator to biosimilar infliximab in patients with spondyloarthritis: a 6-month real-life observational study.
    Benucci M, Gobbi FL, Bandinelli F, Damiani A, Infantino M, Grossi V, Manfredi M, Parisi S, Fusaro E, Batticciotto A, Sarzi-Puttini P, Atzeni F, Meacci F.
    Immunol Res; 2017 Feb 18; 65(1):419-422. PubMed ID: 27449503
    [Abstract] [Full Text] [Related]

  • 54.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 55.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 56.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 57. Use of biosimilars in inflammatory bowel disease: a position update of the Italian Group for the Study of Inflammatory Bowel Disease (IG-IBD).
    Fiorino G, Caprioli F, Daperno M, Mocciaro F, Principi M, Viscido A, Fantini MC, Orlando A, Papi C, Annese V, Danese S, Vecchi M, Rizzello F, Armuzzi A, National patients’ association representatives.
    Dig Liver Dis; 2019 May 18; 51(5):632-639. PubMed ID: 30872085
    [Abstract] [Full Text] [Related]

  • 58. An online survey among US patients with immune-mediated conditions: Attitudes about biosimilars.
    Gibofsky A, Jacobson G, Franklin A, O'Hara-Levi S, Peyrin-Biroulet L, McGrath M, McCabe D.
    J Manag Care Spec Pharm; 2023 Apr 18; 29(4):343-349. PubMed ID: 36989450
    [Abstract] [Full Text] [Related]

  • 59. Introduction of Biosimilar Therapeutics Into Nephrology Practice in the United States: Report of a Scientific Workshop Sponsored by the National Kidney Foundation.
    Wish JB, Charytan C, Chertow GM, Kalantar-Zadeh K, Kliger AS, Rubin RJ, Yee J, Fishbane S.
    Am J Kidney Dis; 2016 Dec 18; 68(6):843-852. PubMed ID: 27599628
    [Abstract] [Full Text] [Related]

  • 60.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 47.